Esperion Therapeutics (ESPR) Tops Q1 EPS by 9c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.65), $0.09 better than the analyst estimate of ($0.74).

As of March 31, 2016, cash and cash equivalents and available-for-sale investment securities totaled $282.7 million compared with $292.6 million at December 31, 2015.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Flowserve acquires Trillium valves division for $490 million
• Halozyme names David Ramsay as president of drug delivery